Free Trial
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

Pieris Pharmaceuticals logo
$16.01 +0.42 (+2.69%)
(As of 11/20/2024 ET)

About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)

Key Stats

Today's Range
$15.59
$16.25
50-Day Range
$15.44
$17.30
52-Week Range
$6.20
$22.32
Volume
8,045 shs
Average Volume
37,842 shs
Market Capitalization
$21.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Pieris Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
33rd Percentile Overall Score

PIRS MarketRank™: 

Pieris Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 815th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pieris Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pieris Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pieris Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pieris Pharmaceuticals has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.70% of the float of Pieris Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Pieris Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pieris Pharmaceuticals has recently decreased by 16.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pieris Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Pieris Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.70% of the float of Pieris Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Pieris Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pieris Pharmaceuticals has recently decreased by 16.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pieris Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pieris Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.39% of the stock of Pieris Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pieris Pharmaceuticals' insider trading history.
Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
See More Headlines

PIRS Stock Analysis - Frequently Asked Questions

Pieris Pharmaceuticals' stock was trading at $14.56 at the beginning of 2024. Since then, PIRS stock has increased by 10.0% and is now trading at $16.01.
View the best growth stocks for 2024 here
.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, hitting the consensus estimate of ($19.20). The biotechnology company had revenue of $4.06 million for the quarter, compared to the consensus estimate of $7.98 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 80.93% and a negative net margin of 39.71%.

Pieris Pharmaceuticals's stock reverse split on Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Pieris Pharmaceuticals' top institutional investors include BML Capital Management LLC (3.19%) and Frazier Life Sciences Management L.P. (1.21%). Insiders that own company stock include Adar1 Capital Management, Llc, Christopher P Kiritsy and Tim Demuth.
View institutional ownership trends
.

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), General Electric (GE) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/02/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PIRS
Employees
140
Year Founded
N/A

Profitability

Net Income
$-24,540,000.00
Pretax Margin
-1,179.96%

Debt

Sales & Book Value

Annual Sales
$42.81 million
Book Value
$12.32 per share

Miscellaneous

Free Float
1,236,000
Market Cap
$21.13 million
Optionable
Optionable
Beta
0.66

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:PIRS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners